This activity was originally presented at the 2026 Cardiology Day of Education.
Endorsed by the American College of Cardiology
Disclaimer: ACCF makes no guarantees or promises regarding the contents of PTCE’s program.
Program Information
Transthyretin amyloidosis cardiomyopathy (ATTR-CM) carries a
substantial and historically underestimated clinical burden, especially among
patients with heart failure with preserved ejection fraction (HFpEF). Due to
its overlapping presentation with HFpEF and other cardiovascular conditions,
ATTR-CM remains frequently underrecognized and undiagnosed. Compounding this
challenge is that patients with ATTR-CM may have suboptimal responses to
standard heart failure therapies, which can serve as an important clinical clue
warranting further evaluation. Early detection of ATTR-CM is paramount, as
disease-modifying therapies (DMTs) demonstrate the greatest benefit when
initiated in earlier stages. Although the American College of Cardiology
released a Concise Clinical Guidance report on the evaluation and management of
ATTR-CM, alongside the ACC Expert Consensus Decision Pathway and the AHA
Scientific Statement on its evolving diagnosis and management, evidence
suggests that these recommendations are not being integrated routinely into
clinical decision-making. This session will equip pharmacists to recognize
ATTR-CM pathophysiology to facilitate timely diagnostic workups. Faculty will
outline the expanding treatment landscape, while emphasizing the pharmacist’s
pivotal role across the care continuum including navigating specialty pharmacy
distribution, managing drug interactions and medication use, treatment
adjustment based on relevant laboratory values, and delivering patient-centered
counseling.
Target audience: Community pharmacists
Type of activity: Application
Release date: June 25, 2026
Expiration date: June 25, 2027
Learner level: Foundational, Intermediate
Time to complete activity: 1.5 hours
Fee: Free
Educational Objectives
At the completion of this activity, participants will be able to:
- Investigate the clinical burden of transthyretin amyloidosis cardiomyopathy (ATTR-CM) and screening protocols to prevent misdiagnosis
- Examine the guideline recommendations and evidence supporting the use of emerging and novel therapies for ATTR-CM to inform formulary decisions and patient access strategies
- Express multidisciplinary efforts that increase awareness of ATTR-CM and enable appropriate and early patient identification
- Apply data-driven, value-based care strategies to optimize access to ATTR-CM therapies
GET STARTED WITH THIS PROGRAM:
Register now to gain access to this program.
Create AccountAlready Registered? Login Here
